Voronoi Co. Ltd.

Voronoi, Inc. is a South Korean company that researches, develops, and discovers small molecule kinase inhibitors. Its pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme for brain and pancreatic cancers; VRN07, VRN06, and VRN11 for lung cancer; VRN08 and VRN10 for breast cancer; and VRN02 for rheumatoid arthritis and atopic dermatitis. Additional candidates include VRN04-1 for autoimmune diseases, VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis, VRN13 for pulmonary arterial hypertension, and VRN14 for refractory solid cancer. Incorporated in 2015, the company is based in Incheon, South Korea.